Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  acetylcysteine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-6 of 6 for your search:
Start Over
THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NAC+Cisplatin2014, NCT02241876
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI50308, NCT01612221
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12D.396, NCT01878695
NAC to Prevent Cisplatin-induced Hearing Loss
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: NACCDDP1, NCT02094625
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LTC-510-100108-Bahce, CCMO: NL19614.091.07, EudraCT: 2007-002787-95, NCT00637624
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC13C2, NCI-2014-00865, Mod13-007632-07, P30CA015083, NCT02123511
Start Over